Therapeutic Potential of Ex Vivo Expanded Endothelial Progenitor Cells for Myocardial Ischemia
- 6 February 2001
- journal article
- other
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 103 (5), 634-637
- https://doi.org/10.1161/01.cir.103.5.634
Abstract
Background —We investigated the therapeutic potential of ex vivo expanded endothelial progenitor cells (EPCs) for myocardial neovascularization. Methods and Results —Peripheral blood mononuclear cells obtained from healthy human adults were cultured in EPC medium and harvested 7 days later. Myocardial ischemia was induced by ligating the left anterior descending coronary artery in male Hsd:RH-rnu (athymic nude) rats. A total of 10 6 EPCs labeled with 1,1′-dioctadecyl-1 to 3,3,3′,3′-tetramethylindocarbocyanine perchlorate were injected intravenously 3 hours after the induction of myocardial ischemia. Seven days later, fluorescence-conjugated Bandeiraea simplicifolia lectin I was administered intravenously, and the rats were immediately killed. Fluorescence microscopy revealed that transplanted EPCs accumulated in the ischemic area and incorporated into foci of myocardial neovascularization. To determine the impact on left ventricular function, 5 rats (EPC group) were injected intravenously with 10 6 EPCs 3 hours after ischemia; 5 other rats (control group) received culture media. Echocardiography, performed just before and 28 days after ischemia, disclosed ventricular dimensions that were significantly smaller and fractional shortening that was significantly greater in the EPC group than in the control group by day 28. Regional wall motion was better preserved in the EPC group. After euthanization on day 28, necropsy examination disclosed that capillary density was significantly greater in the EPC group than in the control group. Moreover, the extent of left ventricular scarring was significantly less in rats receiving EPCs than in controls. Immunohistochemistry revealed capillaries that were positive for human-specific endothelial cells. Conclusions —Ex vivo expanded EPCs incorporate into foci of myocardial neovascularization and have a favorable impact on the preservation of left ventricular function.Keywords
This publication has 9 references indexed in Scilit:
- Enhancement of Angiogenesis by the Implantation of Self Bone Marrow Cells in a Rat Ischemic Heart ModelJournal of Surgical Research, 2000
- Transplantation ofex vivoexpanded endothelial progenitor cells for therapeutic neovascularizationProceedings of the National Academy of Sciences of the United States of America, 2000
- Origins of circulating endothelial cells and endothelial outgrowth from bloodJCI Insight, 2000
- Ascending Aortic Replacement With Aortic Valve ReimplantationCirculation, 1999
- Gene therapy with vascular endothelial growth factor for inoperable coronary artery diseaseThe Annals of Thoracic Surgery, 1999
- VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cellsThe EMBO Journal, 1999
- Evidence for Circulating Bone Marrow-Derived Endothelial CellsBlood, 1998
- Intracoronary gene transfer of fibroblast growth factor–5 increases blood flow and contractile function in an ischemic region of the heartNature Medicine, 1996
- Recommendations for Quantitation of the Left Ventricle by Two-Dimensional EchocardiographyJournal of the American Society of Echocardiography, 1989